INPHARMATION
INPHARMATION, a leading provider of market access and commercialisation solutions, is headquartered in Great Britain and operates extensively across Europe and North America. Founded in 2001, the company has established itself as a key player in the pharmaceutical and biotechnology sectors, focusing on delivering strategic insights and data-driven solutions. Specialising in market access, pricing, and reimbursement strategies, INPHARMATION offers unique services that empower clients to navigate complex healthcare environments. Their innovative approach combines deep industry knowledge with advanced analytics, ensuring tailored solutions that meet the specific needs of their clients. With a strong reputation for excellence, INPHARMATION has achieved significant milestones, including partnerships with major pharmaceutical companies and contributions to successful product launches. Their commitment to quality and client satisfaction positions them as a trusted partner in the ever-evolving landscape of healthcare.
DitchCarbon Score
How does INPHARMATION's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Business Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
INPHARMATION's score of 3 is higher than 50% of the industry. This can give you a sense of how well the company is doing compared to its peers.
INPHARMATION's reported carbon emissions
INPHARMATION, headquartered in Great Britain, currently does not have available carbon emissions data for the most recent year. As a result, specific figures regarding their emissions in kg CO2e, including Scope 1, 2, or 3 emissions, are not provided. Additionally, there are no documented reduction targets or climate pledges outlined in their initiatives. This absence of data suggests that INPHARMATION may still be in the early stages of formalising its climate commitments or may not have publicly disclosed its strategies for reducing carbon emissions. In the context of the industry, it is increasingly important for companies to establish clear climate commitments and reduction targets to align with global sustainability goals. Without specific emissions data or reduction initiatives, INPHARMATION's current climate impact remains unclear.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
INPHARMATION is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
